Heparin-Binding Haemagglutinin, a New Tool for the Detection of Latent Mycobacterium tuberculosis Infection in Hemodialysis Patients

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Dessein, Rodrigue ^a   Corbière, Véronique ^a   Nortier, Joëlle ^b   Dratwa, Max ^c   Gastaldello, Karine ^b   Pozdzik, Agnieszka ^b   Lecher, Sophie ^d,e,f   Grandbastien, Bruno ^f,g   Locht, Camille ^d,e,f   Mascart, Françoise ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^d INSERM   (France)

^e INSERM U1019   (France)

^f UNIV LILLE   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; HEPARIN BINDING HEMAGGLUTININ; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TUBERCULIN TEST;

EID: 84881116501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071088     Document Type: Article

References (42)

1. WHO (2011) Available: http://www.who.int/tb/publications/global_report/2011/update/en/index.html. 2011.
2. Young DB, Gideon HP, Wilkinson RJ, (2009) Eliminating latent tuberculosis. Trends Microbiol 17: 183-188.
3. Jasmer RM, Nahid P, Hopewell PC, (2002) Clinical practice. Latent tuberculosis infection. N Engl J Med 347: 1860-1866.
4. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, et al. (2002) European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 19: 765-775.
5. Richeldi L, Losi M, D'Amico R, Luppi M, Ferrari A, et al. (2009) Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 136: 198-204.
6. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, et al. (2011) Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37: 88-99.
7. Segall L, Covic A, (2010) Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol 5: 1114-1122.
8. Simon TA, Paul S, Wartenberg D, Tokars JI, (1999) Tuberculosis in hemodialysis patients in New Jersey: a statewide study. Infect Control Hosp Epidemiol 20: 607-609.
9. Cengiz K, (1996) Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron 73: 421-424.
10. Malhotra KK, Parashar MK, Sharma RK, Bhuyan UN, Dash SC, et al. (1981) Tuberculosis in maintenance haemodialysis patients. Study from an endemic area. Postgrad Med J 57: 492-498.
11. Chou KJ, Fang HC, Bai KJ, Hwang SJ, Yang WC, et al. (2001) Tuberculosis in maintenance dialysis patients. Nephron 88: 138-143.
12. Moore DA, Lightstone L, Javid B, Friedland JS, (2002) High rates of tuberculosis in end-stage renal failure: the impact of international migration. Emerg Infect Dis 8: 77-78.
13. Rose DN, (2000) Benefits of screening for latent Mycobacterium tuberculosis infection. Arch Intern Med 160: 1513-1521.
14. Richardson RM, (2012) The diagnosis of tuberculosis in dialysis patients. Seminars in dialysis 25: 419-422.
15. Girndt M, Sester U, Sester M, Kaul H, Kohler H, (1999) Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 14: 2807-2810.
16. Passalent L, Khan K, Richardson R, Wang J, Dedier H, et al. (2007) Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol 2: 68-73.
17. Lee SS, Chou KJ, Su IJ, Chen YS, Fang HC, et al. (2009) High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection 37: 96-102.
18. Winthrop KL, Nyendak M, Calvet H, Oh P, Lo M, et al. (2008) Interferon-gamma release assays for diagnosing Mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 3: 1357-1363.
19. Triverio PA, Bridevaux PO, Roux-Lombard P, Niksic L, Rochat T, et al. (2009) Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant 24: 1952-1956.
20. Seyhan EC, Sokucu S, Altin S, Gunluoglu G, Trablus S, et al. (2009) Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection in hemodialysis patients. Transpl Infect Dis 12: 98-105.
21. Smirnoff M, Patt C, Seckler B, Adler JJ, (1998) Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 113: 25-27.
22. Sester M, Sester U, Clauer P, Heine G, Mack U, et al. (2004) Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int 65: 1826-1834.
23. Rogerson TE, Chen S, Kok J, Hayen A, Craig JC, et al. (2012) Tests for Latent Tuberculosis in People With ESRD: A Systematic Review. Am J Kidney Dis 61: 33-43.
24. Hoffmann M, Tsinalis D, Vernazza P, Fierz W, Binet I, (2010) Assessment of an Interferon-gamma release assay for the diagnosis of latent tuberculosis infection in haemodialysis patient. Swiss Med Wkly 140: 286-292.
25. Petrescu L, Stancu S, Tardei G, Santimbrean C, Penescu M, et al. (2010) Tuberculin skin test, interferon-gamma assay, and T cells subpopulations in hemodialysis patients. J Ren Nutr 20: S109-117.
26. Chung WK, Zheng ZL, Sung JY, Kim S, Lee HH, et al. (2010) Validity of interferon-gamma-release assays for the diagnosis of latent tuberculosis in haemodialysis patients. Clin Microbiol Infect 16: 960-965.
27. Shu CC, Wu VC, Yang FJ, Pan SC, Lai TS, et al. (2012) Predictors and prevalence of latent tuberculosis infection in patients receiving long-term hemodialysis and peritoneal dialysis. PloS one 7: e42592.
28. Hougardy JM, Schepers K, Place S, Drowart A, Lechevin V, et al. (2007) Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PloS one 2: e926.
29. Leyten EMS, Arend SM, Prins C, Cobelens FGJ, Ottenhoff THM, et al. (2007) Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol 14: 880-885.
30. Corbière V, Pottier G, Bonkain F, Schepers K, Verscheure V, et al. (2012) Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PloS one 7: e43285.
31. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, et al. (2006) Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 13: 179-186.
32. Goletti D, Butera O, Vanini V, Lauria FN, Lange C, et al. (2010) Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 36: 135-142.
33. Centers for Disease Control and Prevention (2011) Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morbidity and mortality weekly report 60: 1650-1653.
34. Hursitoglu M, Cikrikcioglu MA, Tukek T, Beycan I, Ahmedova N, et al. (2009) Acute effect of low-flux hemodialysis process on the results of the interferon-gamma-based QuantiFERON-TB Gold In-Tube test in end-stage renal disease patients. Transpl Infect Dis 11: 28-32.
35. Masungi C, Temmerman S, Van Vooren JP, Drowart A, Pethe K, et al. (2002) Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis 185: 513-520.
36. Menozzi FD, Rouse JH, Alavi M, Laude-Sharp M, Muller J, et al. (1996) Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 184: 993-1001.
37. Feske M, Nudelman RJ, Medina M, Lew J, Singh M, et al. (2008) Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. Clin Vaccine Immunol 15: 1616-1622.
38. Hosmer D, Lemeshow S (1989) Applied logistic regression, 2nd ed: John Wiley & sons, Inc. 392p.
39. Cohen J, (1960) A coefficient of agreement for nominal scales. Educational and Psychological Measurement 20: 37-46.
40. Temmerman S, Pethe K, Parra M, Alonso S, Rouanet C, et al. (2004) Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 10: 935-941.
41. Locht C, Hougardy JM, Rouanet C, Place S, Mascart F, (2006) Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis 86: 303-309.
42. Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, et al. (2002) Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 40: 704-706.